drugset / Trial / NCT00669344
RIVastigmine In Vascular cognitivE Impairment
Phase 4
Completed
50 enrolled
Singapore General Hospital
National Neuroscience Institute · collabNovartis · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The study is a 24-week prospective, double blind, randomized, placebo-controlled pilot study of 9 mg / day Rivastigmine in patients with Vascular Cognitive Impairment Not Dementia (CIND) to evaluate efficacy, safety and tolerability in Asian patients. The hypothesis is that patients receiving Rivastigmine would improve in executive functioning domains.
Timeline
- Start
- 2006-02
- Primary completion
- 2007-04
- Completion
- 2008-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivastigmine | Small molecule | 4.5 mg | Oral |